Literature DB >> 7496594

Relationship between ERBB2 and E-cadherin expression in human breast cancer.

J Palacios1, N Benito, A Pizarro, M A Limeres, A Suárez, A Cano, C Gamallo.   

Abstract

A recent in vitro study has suggested that overexpression of ERBB2 may mediate breast tumour progression and metastasis by inhibiting the transcription of the E-cadherin (E-CD) gene. To test this hypothesis in human breast cancer in vivo, we studied the relationship between the expression of both molecules in 247 breast carcinomas immunohistochemically. Five ductal carcinomas in situ overexpressed ERBB2 and showed preserved E-CD expression. Forty-four of 226 infiltrating ductal carcinomas (19.47%) showed ERBB2 overexpression, and a statistically significant relationship was found between ERBB2 overexpression and high histological grade. E-CD expression was preserved in 111 cases (49.1%) and correlated with the histological grade. However, no significant relationship was found between ERBB2 and E-CD expression. None of the 16 infiltrating lobular carcinomas expressed ERBB2 or E-CD. These observations in different histological types of breast carcinoma strongly argue against a role for ERBB2 as a transcriptional regulator of E-CD expression in most human breast carcinomas in vivo.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7496594     DOI: 10.1007/bf00203392

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  28 in total

1.  Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.

Authors:  M C Paterson; K D Dietrich; J Danyluk; A H Paterson; A W Lees; N Jamil; J Hanson; H Jenkins; B E Krause; W A McBlain
Journal:  Cancer Res       Date:  1991-01-15       Impact factor: 12.701

2.  Overexpression of ERBB2 in human mammary epithelial cells signals inhibition of transcription of the E-cadherin gene.

Authors:  B D'souza; J Taylor-Papadimitriou
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-19       Impact factor: 11.205

3.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

4.  Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers.

Authors:  D R Ciocca; F K Fujimura; A K Tandon; G M Clark; C Mark; G J Lee-Chen; G W Pounds; P Vendely; M A Owens; M R Pandian
Journal:  J Natl Cancer Inst       Date:  1992-08-19       Impact factor: 13.506

5.  Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

Authors:  B A Gusterson; R D Gelber; A Goldhirsch; K N Price; J Säve-Söderborgh; R Anbazhagan; J Styles; C M Rudenstam; R Golouh; R Reed
Journal:  J Clin Oncol       Date:  1992-07       Impact factor: 44.544

6.  Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas.

Authors:  R Moll; M Mitze; U H Frixen; W Birchmeier
Journal:  Am J Pathol       Date:  1993-12       Impact factor: 4.307

7.  The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor.

Authors:  A L Schechter; M C Hung; L Vaidyanathan; R A Weinberg; T L Yang-Feng; U Francke; A Ullrich; L Coussens
Journal:  Science       Date:  1985-09-06       Impact factor: 47.728

8.  Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ.

Authors:  J Bartkova; D M Barnes; R R Millis; W J Gullick
Journal:  Hum Pathol       Date:  1990-11       Impact factor: 3.466

Review 9.  William L. McGuire Memorial Symposium. The role of erbB2 signal transduction pathways in human breast cancer.

Authors:  R Lupu; M E Lippman
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

10.  E-cadherin expression in basal cell carcinoma.

Authors:  A Pizarro; N Benito; P Navarro; J Palacios; A Cano; M Quintanilla; F Contreras; C Gamallo
Journal:  Br J Cancer       Date:  1994-01       Impact factor: 7.640

View more
  2 in total

1.  Repression of E-cadherin by the polycomb group protein EZH2 in cancer.

Authors:  Q Cao; J Yu; S M Dhanasekaran; J H Kim; R-S Mani; S A Tomlins; R Mehra; B Laxman; X Cao; J Yu; C G Kleer; S Varambally; A M Chinnaiyan
Journal:  Oncogene       Date:  2008-09-22       Impact factor: 9.867

2.  Expression of e-cadherin in high-risk breast cancer.

Authors:  Eugene M Howard; Stephen K Lau; Robert H Lyles; George G Birdsong; Jay N Umbreit; Ruby Kochhar
Journal:  J Cancer Res Clin Oncol       Date:  2004-10-01       Impact factor: 4.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.